Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
No-code website development platform company Webflow Inc. today launched App Gen, a new artificial intelligence-powered code generation experience that allows anyone, from designers to marketers to ...
After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...
Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...
NVIDIA unveiled a new artificial intelligence-enabled wireless stack structured to handle data-heavy workloads alongside tech contractor Booz Allen at its GTC event Tuesday. The NVIDIA-Booz Allen ...
Harris started looking for his first real job months before his graduation from UC Davis this spring. He had a solid résumé, he thought: a paid internship at a civic-consulting firm, years of ...
A burst of experimentation followed ChatGPT's release to the public in late 2022. Now many people are integrating the newest models and custom systems into what they do all day: their work. Chefs are ...
More developers than ever before are using AI tools to both assist and generate code. While enterprise AI adoption accelerates, new data from Stack Overflow's 2025 Developer Survey exposes a critical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback